Adults (≥18 years of age) with a confirmed diagnosis of Systemic Lupus Erythematosus
Evidence of active disease at screening
Willing and able to provide written informed consent
You may not be if
Have other autoimmune diseases that may interfere with the assessment of SLE
Prior or recent use of prohibited immunomodulatory therapies
Clinically significant infections, malignancies, or uncontrolled medical conditions
Pregnancy or breastfeeding
Clareo Health | A Phase 2 Study on the Safety and Efficacy of the Anti-BAFF-R Monoclonal Antibody, ESG206, in Patients With Systemic Lupus Erythematosus
